Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.
Israeli firm IOPtima has completed development of its novel laser-based therapy for the treatment of glaucoma, OT134.
The second-generation OT134 system is based on the company's smart laser-based technology known as LNPDS (CO2 Laser Non-Penetrating Deep Sclerectomy) that has already undergone successful testing on 23 patients in clinical trials. The OT134 upgrades have been designed to offer improved efficacy and ergonomics.
IOPtima plans to initiate a multinational, long-term, human clinical trial later this year.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.